Breaking News, Collaborations & Alliances

AZ, Array Biopharma Cancer Program Advances

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Array BioPharma and AstraZeneca have selected a third compound for their small molecule MEK anti-cancer program, triggering a $1 million milestone payment by AstraZeneca. The second compound was selected in January 2006, also triggering a $1 million milestone to Array.  In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-142886 (AZD6244), for co-development and commercialization with AZ.  At that time, the companies established a collabora...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters